Asclepix Therapeutics, Inc. AsclepiX Therapeutics Announces $35 Million Series A Financing Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing…
Read More
Read news items items specific to Ponce Therapeutics or about other Rapha Capital-related entities. Also see scientific articles detailing the rapid advances in the important science of anti-aging
News
Poseida Therapeutics, Inc. Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer May 20, 2020
FIZE Medical Ltd. Rapha Capital Management Leads Series A Financing for FIZE Medical Ltd FIZE’s Novel Device Conquers the Last Frontier in Patient Monitoring May 4, 2020
Asclepix Therapeutics, Inc. AsclepiX Therapeutics, Inc. Expands Leadership Team with Appointment of Industry Leader Theresa Heah, MD, MBA as Chief Medical Officer January 6, 2020
ControlRad, Inc. ControlRad Adds Five People to Leadership Team December 17, 2019
NexImmune Inc. NexImmune Appoints Sol Barer as Chairman of the Board of Directors December 16, 2019